Antihistamine recommendations
This article was originally published in The Tan Sheet
Executive Summary
Allergies should be treated with newer, non-impairing, second-generation antihistamines rather than with older medications such as Pfizer's Benadryl, according to recommendations developed by a panel of 14 experts and published in the May Journal of Allergy and Clinical Immunology. Many antihistamines used to treat allergic rhinitis "may produce sedation, impairment and reduced quality of life," experts state, noting the condition is "more appropriately managed with the relatively non-impairing second-generation antihistamines" such as loratadine (Schering's Claritin). While "further epidemiologic studies on the effects of antihistamines should be performed," the expert group advises physicians that "second generation antihistamines are preferred for all patients"...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.